Literature DB >> 12197428

Bacteriology and antimicrobial susceptibility in biliary tract disease: an audit of 10-year's experience.

Wen-Tsan Chang1, King-Teh Lee, Sen-Ren Wang, Shin-Chang Chuang, Kung-Kai Kuo, Jong-Shyone Chen, Pai-Ching Sheen.   

Abstract

Cholelithiasis, choledocholithiasis and hepatolithiasis are common biliary tract diseases. These diseases may cause severe infection and/or sepsis. In addition to surgical treatments, prompt administration of appropriate antibiotic is important to control the biliary tract infection. The purpose of this study is to illustrate the bacteriology in biliary tract disease and provide information for antibiotic choices. From Jan 1991 to Aug 2000, 1394 patients including gallbladder (GB) stones, common bile duct (CBD) stones, intrahepatic duct (IHD) stones, GB polyps and biliary malignancy were subjects for this retrospective study. The overall positive rate of bile culture is 36% in this study while it was 25%, 66%, 67% and 9% for GB stones, CBD stones, IHD stones and biliary malignancy, respectively. A significantly higher (p = 0.001) positive culture rate was found for GB stones with acute cholecystits (47%) compared with that without inflammation (17%). Similarly, the culture rate for hepatolithiasis with acute cholangitis was higher than that without cholangitis (75% vs 51%, p = 0.011). Long-term external biliary drainage in biliary malignancy increased the risk of bacterial culture rate. For gallstone diseases, the most common organisms cultured were Gram negative bacteria (74%), in which Escherichia coli (36%) and Klebsiella (15%) were most commonly found, followed by Gram positive (15%) bacteria such as Enterococcus (6%), Staphylcoccus (3%), Streptococcus (2%). Bacteroides (5%) and Clostridium (3%) were occasionally found anaerobes (9%). Polymicrobial infection was encountered in 19%, 31% and 29% for patients with GB stones, CBD stones and IHD stones, respectively; frequency of mixed aerobic and anaerobic infection was 7%, 12% and 9%. In the current study, ampicillin in combination with sulbactam and aminoglycoside is still a suggestive empirical therapy. Antibiotic treatment should be adjusted based on later bacteriological cultures and clinical condition.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12197428

Source DB:  PubMed          Journal:  Kaohsiung J Med Sci        ISSN: 1607-551X            Impact factor:   2.744


  18 in total

1.  Empirical antibiotic treatment with piperacillin-tazobactam in patients with microbiologically-documented biliary tract infections.

Authors:  Gabrio Bassotti; Fabio Chistolini; Francis Sietchiping-Nzepa; Giuseppe De-Roberto; Antonio Morelli
Journal:  World J Gastroenterol       Date:  2004-08-01       Impact factor: 5.742

2.  Intravenous Versus Oral Antibiotic Prophylaxis Efficacy for Elective Laparoscopic Cholecystectomies: a Prospective Randomized Controlled Trial.

Authors:  A Serdar Karaca; Haldun Gündoğdu; Mehmet Özdoğan; Eren Ersoy
Journal:  Indian J Surg       Date:  2013-08-03       Impact factor: 0.656

3.  Microbial profile and antibiotic sensitivity pattern in acute bacterial cholangitis.

Authors:  Manoj Kumar Sahu; Ashok Chacko; Amit Kumar Dutta; John Antony Jude Prakash
Journal:  Indian J Gastroenterol       Date:  2011-10-18

4.  Wound classification reporting in HPB surgery: can a single word change public perception of institutional performance?

Authors:  Paul J Speicher; Daniel P Nussbaum; John E Scarborough; Sabino Zani; Rebekah R White; Dan G Blazer; Christopher R Mantyh; Douglas S Tyler; Bryan M Clary
Journal:  HPB (Oxford)       Date:  2014-05-23       Impact factor: 3.647

5.  Role of Prophylactic Antibiotics in Laparoscopic Cholecystectomy.

Authors:  A Gaur; A K Pujahari
Journal:  Med J Armed Forces India       Date:  2011-07-21

6.  Microbial profile and antibiotic sensitivity pattern in bile cultures from endoscopic retrograde cholangiography patients.

Authors:  Muhsin Kaya; Remzi Beştaş; Fatma Bacalan; Ferhat Bacaksız; Esma Gülsun Arslan; Mehmet Ali Kaplan
Journal:  World J Gastroenterol       Date:  2012-07-21       Impact factor: 5.742

7.  Prospective observational multicenter study to define a diagnostic algorithm for biliary candidiasis.

Authors:  Philipp Lenz; Franziska Eckelskemper; Thomas Erichsen; Tim Lankisch; Alexander Dechêne; Gabriele Lubritz; Frank Lenze; Torsten Beyna; Hansjörg Ullerich; Andre Schmedt; Dirk Domagk
Journal:  World J Gastroenterol       Date:  2014-09-14       Impact factor: 5.742

8.  Risk factors of organ failure in cholangitis with bacteriobilia.

Authors:  Jae Min Lee; Sang Hyub Lee; Kwang Hyun Chung; Jin Myung Park; Ban Seok Lee; Woo Hyun Paik; Joo Kyung Park; Ji Kon Ryu; Yong-Tae Kim
Journal:  World J Gastroenterol       Date:  2015-06-28       Impact factor: 5.742

9.  Antimicrobial therapy for acute cholangitis: Tokyo Guidelines.

Authors:  Atsushi Tanaka; Tadahiro Takada; Yoshifumi Kawarada; Yuji Nimura; Masahiro Yoshida; Fumihiko Miura; Masahiko Hirota; Keita Wada; Toshihiko Mayumi; Harumi Gomi; Joseph S Solomkin; Steven M Strasberg; Henry A Pitt; Jacques Belghiti; Eduardo de Santibanes; Robert Padbury; Miin-Fu Chen; Giulio Belli; Chen-Guo Ker; Serafin C Hilvano; Sheung-Tat Fan; Kui-Hin Liau
Journal:  J Hepatobiliary Pancreat Surg       Date:  2007-01-30

10.  Antimicrobial therapy for acute cholecystitis: Tokyo Guidelines.

Authors:  Masahiro Yoshida; Tadahiro Takada; Yoshifumi Kawarada; Atsushi Tanaka; Yuji Nimura; Harumi Gomi; Masahiko Hirota; Fumihiko Miura; Keita Wada; Toshihiko Mayumi; Joseph S Solomkin; Steven Strasberg; Henry A Pitt; Jacques Belghiti; Eduardo de Santibanes; Sheung-Tat Fan; Miin-Fu Chen; Giulio Belli; Serafin C Hilvano; Sun-Whe Kim; Chen-Guo Ker
Journal:  J Hepatobiliary Pancreat Surg       Date:  2007-01-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.